TY - JOUR
T1 - p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel
AU - Debernardis, Domizia
AU - Siré, Eva Graniela
AU - De Feudis, Paola
AU - Vikhanskaya, Faina
AU - Valenti, Monica
AU - Russo, Patrizia
AU - Parodi, Silvio
AU - D'Incalci, Maurizio
AU - Broggini, Massimo
PY - 1997
Y1 - 1997
N2 - Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated p53-expressing cell lines was not different from the four wt p53-expressing cell lines. The introduction of wt p53, by using a temperature-sensitive mutant murine p53 or the human p53 under the control of a tetracycline-dependent promoter, did not change the cytotoxicity of paclitaxel as compared to mock-transfected cells. By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected. This increase in p53 levels led to an increase in the mRNA and protein levels of p53 downstream genes (WAF1, GADD45, and bax). In none of the cell lines examined was paclitaxel able to induce apoptosis, evaluated by terminal deoxynucleotidyl transferase-mediated nick end labeling staining and filter binding assay at concentration closed to the IC50. By increasing the concentration of paclitaxel in the filter binding assay, we could see fragmentation of DNA in the different cell lines. We conclude that the presence of p53 is not a determinant for the cytotoxicity induced by paclitaxel in human ovarian cancer cell lines. Differences in the activation of p53 downstream genes could be observed in wt versus mutated p53- expressing cells, but this does not account either fur a differential induction of apoptosis or for a change in cytotoxicity induced by paclitaxel.
AB - Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated p53-expressing cell lines was not different from the four wt p53-expressing cell lines. The introduction of wt p53, by using a temperature-sensitive mutant murine p53 or the human p53 under the control of a tetracycline-dependent promoter, did not change the cytotoxicity of paclitaxel as compared to mock-transfected cells. By using for each cell line the paclitaxel IC50, we found that these concentrations were sufficient to induce an increase in p53 levels in all of the four wt p53-expressing cells, whereas in the mutated p53-expressing cells, the levels were unaffected. This increase in p53 levels led to an increase in the mRNA and protein levels of p53 downstream genes (WAF1, GADD45, and bax). In none of the cell lines examined was paclitaxel able to induce apoptosis, evaluated by terminal deoxynucleotidyl transferase-mediated nick end labeling staining and filter binding assay at concentration closed to the IC50. By increasing the concentration of paclitaxel in the filter binding assay, we could see fragmentation of DNA in the different cell lines. We conclude that the presence of p53 is not a determinant for the cytotoxicity induced by paclitaxel in human ovarian cancer cell lines. Differences in the activation of p53 downstream genes could be observed in wt versus mutated p53- expressing cells, but this does not account either fur a differential induction of apoptosis or for a change in cytotoxicity induced by paclitaxel.
UR - http://www.scopus.com/inward/record.url?scp=0031036695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031036695&partnerID=8YFLogxK
M3 - Article
C2 - 9041188
AN - SCOPUS:0031036695
VL - 57
SP - 870
EP - 874
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0008-5472
IS - 5
ER -